- FDA's decision to lift import alert paves the way for Apotex's oral solid dose products to be available again for US consumers; Company moves forward to restore pipeline of shipments to the local market -
To view the Social Media Release, click here: http://smr.newswire.ca/en/apotex-inc/apotex-resumes-shipping-to-the-us
TORONTO, May 11 /PRNewswire/ - Apotex, one of the largest generic pharmaceutical manufacturers in the world, announced it will soon resume shipments of its oral solid dose products to the U.S. market. The announcement comes on the heels of a Food and Drug Administration (FDA) decision to lift its import alert at Apotex's largest solid dose manufacturing facility supplying product to the US.
"Apotex is pleased the FDA has recognized the enhancements to our global quality systems," stated Dr Jeremy B. Desai, Apotex' Chief Operating Officer.
Apotex will immediately resume manufacturing and shipping of our solid dose products into the US market.
Apotex Inc., with 6000 employees in Canada sells to 115 countries a portfolio of approximately 300 affordable medicines around the globe and is the largest generic company in the country. It is the top research and development Canadian corporation in the pharmaceutical industry with planned expenditures of $2 billion over the next ten years.
Apotex Corp. is the US Company that markets the products of Apotex, Inc. Through its sales and marketing headquarters in Weston, Florida and operations center in Indianapolis, Apotex Corp. is committed to providing safe and affordable generic medicines.
/NOTE TO EDITORS: Media Assets accompanying this story are available as follows:
SOURCE Apotex Inc.